rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ONCY
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Oncolytics enters supply deal with Coherus for cancer study
      Nov 11Investing.comCHRSONCY
      Stocks in play: Oncolytics Biotech Inc

      Announced translational data in heavily pretreated relapsed/refractory multiple myeloma patients, which ...

      Nov 9Yahoo FinanceONCY
      Stocks in play: Oncolytics Biotech Inc

      Announced updated data from Cohort 4 of its Phase 1/2 GOBLET study evaluating pelareorep in combination ...

      Oct 27Yahoo FinanceONCY
      Oncolytics reports 15-month response duration in anal cancer trial
      Oct 27Investing.comONCY
      Oncolytics Biotech® Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven Cancers

      GOBLET Cohort 4 demonstrates approximately 15-month median duration of response that exceeds historical results for approved second-line checkpoint inhibitor monotherapy 100% of responding patients survived for longer than one year FDA Fast Track Designation and recent regulatory guidance support advancement toward registration and potential expansion into HPV-driven head and neck cancer SAN DIEGO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Co

      Oct 27Yahoo FinanceONCY
      Stocks in play: Oncolytics Biotech Inc

      Announced the Company is presenting a trial-in-progress abstract and e-poster discussing the REO 033 ...

      Oct 20Yahoo FinanceONCY
      Oncolytics Biotech® to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep’s Potential in Colorectal Cancer
      Oct 20Yahoo FinanceONCY
      Stocks in play: Oncolytics Biotech Inc

      Detailed price information for Oncolytics Biotech Inc (ONCY-Q) from The Globe and Mail including charting and trades.

      Oct 14The Globe and MailONCY
      Oncolytics reports GOBLET study enrollment complete
      Oct 14Investing.comONCY
      Oncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment
      Oct 14Yahoo FinanceONCY
      Stocks in play: Oncolytics Biotech Inc

      Provides an update on its intellectual property strategy, outlining progress on new method of use patents ...

      Oct 13Yahoo FinanceONCY
      Oncolytics Biotech Details on Intellectual Property Strategy
      Oct 12Yahoo FinanceONCY
      Oncolytics receives cancer immunotherapy patent in multiple countries
      Oct 12Investing.comONCY
      Oncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update
      Oct 12Yahoo FinanceONCY
      Oncolytics reports pelareorep data in liver cancer study
      Sep 29Investing.comONCY
      Stocks in play: Oncolytics Biotech Inc

      Detailed price information for Oncolytics Biotech Inc (ONCY-Q) from The Globe and Mail including charting and trades.

      Sep 28The Globe and MailONCY
      KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034

      Equity Insider News Commentary - For most of the last four decades, RAS was the target oncology could not hit. That has changed quickly, and the commercial numbers are starting to follow. According to DelveInsight, the KRAS inhibitors market across the seven major markets was valued at approximately $526 million in 2025 and is projected to reach approximately $7.85 billion by 2034, a compound annual growth rate of roughly 35% over its 2024 to 2034 forecast period, with the United States expected

      Sep 28Yahoo FinanceONCY
      3 Clinical-Stage Cancer Stocks With Pristine Balance Sheets

      Rising rates raise the bar for risky science. Meet three clinical-stage cancer stocks with pristine, debt-free balance sheets, plus the screener that surfaces the rest.

      Sep 16Yahoo FinanceGLSIONCY
      Oncolytics reports preclinical data on pelareorep with RAS inhibitor
      Sep 10Investing.comONCY
      Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer
      Sep 10Yahoo FinanceONCY
      Stocks in play: Oncolytics Biotech Inc

      Today announced positive preclinical results evaluating pelareorep in combination with a pan-RAS inhibitor ...

      Sep 10Yahoo FinanceONCY
      ONCY: FDA Provides Alignment on Registrational Pathway for Pelareorep in CRC

      By David Bautz, PhD NASDAQ: ONCY READ THE FULL ONCY RESEARCH REPORT Business Update Alignment Reached with FDA on Potential Registrational Pathway in CRC On August 18, 2026, Oncolytics Biotech, Inc. (NASDAQ: ONCY) announced it had received written feedback from the FDA regarding the potential expansion of the ongoing REO 033 trial into a pivotal Part B study. REO 033 is a randomized study

      Aug 27Yahoo FinanceONCY

      This is the newest page. Registered accounts read further back.